GSK, Vir's Sotrovimab Meets Phase 3 Primary Endpoint, Cuts COVID Hospitalization Risk 79%

Sotrovimab reduced hospitalizations and deaths among high-risk COVID-19 patients, potentially preventing severe illness and mortality.

In the long effort to blunt the worst of a pandemic that has tested the limits of medicine and human endurance, two pharmaceutical companies announced in late June 2021 that a monoclonal antibody called sotrovimab had reduced the risk of severe illness or death among vulnerable COVID-19 patients by 79 percent. The finding, drawn from a trial of over a thousand high-risk outpatients, arrived at the same moment health authorities updated their guidance to recommend the drug — a convergence of evidence and policy that rarely happens so cleanly. It was not a cure, nor a universal answer, but a car

GSK, Vir's Sotrovimab Meets Phase 3 Primary Endpoint, Cuts COVID Hospitalization Risk 79%

Cobertura Relacionada

Recibe The Register en tu bandeja